Agreement Gives Tolerance Bio Worldwide Development Rights Outside Japan
Tolerance Bio, Inc. has entered into an exclusive licensing agreement with Tanabe Pharma Corporation for MT-2990, now renamed TLB-33.
TLB-33 is a clinical-stage monoclonal antibody that targets interleukin-33, or IL-33.
Under the agreement, Tolerance Bio will receive worldwide rights to develop and manufacture TLB-33 across all indications. The company will also have exclusive commercialization rights outside Japan.
Tanabe Pharma will retain commercialization rights in Japan.
Tolerance Bio plans to move TLB-33 into Phase 2 clinical development and study whether the treatment can help preserve thymic function and support immune resilience.
What Is TLB-33?
TLB-33, previously known as MT-2990, is a human immunoglobulin G1, or IgG1, monoclonal antibody.
The antibody binds to and neutralizes IL-33.
IL-33 is a protein released by cells when they experience stress or tissue injury. It can activate both innate and adaptive immune responses.
IL-33 signalling has also been linked to inflammatory processes that may affect thymic function.
Tolerance Bio is investigating whether blocking this pathway could help protect the thymus and maintain immune function.
Why the Thymus Matters
The thymus is an important part of the immune system.
It is where T cells, which play a central role in fighting infections and controlling immune responses, mature.
The thymus is most active earlier in life. As people age, the organ gradually becomes smaller and less active. This process is known as thymic involution.
The thymus can also undergo more rapid changes during certain inflammatory or immune conditions.
As thymic function declines, the body may become less effective at producing new T cells.
This can contribute to weaker immune responses, including greater susceptibility to infections and reduced responses to vaccines.
Changes in immune function can also be associated with other conditions involving cancer and autoimmunity.
Tolerance Bio Wants to Preserve Thymic Function
Tolerance Bio is developing medicines that target thymic biology.
The company believes that maintaining or restoring thymic function could help preserve immune resilience as people age or during certain diseases.
TLB-33 is being developed as one part of this approach.
The company plans to study whether blocking IL-33 can help preserve thymic output and support immune function.
Additional immune-related indications are also being considered.
TLB-33 Has Already Been Studied in More Than 150 People
One of the reasons Tolerance Bio is advancing TLB-33 is that the antibody already has human clinical data.
According to the company, TLB-33, previously MT-2990, has been evaluated in more than 150 subjects across five clinical studies.
These studies have generated information about the drug’s safety, tolerability, pharmacology and clinical effects.
Tolerance Bio believes the existing data provide a foundation for evaluating the antibody in new indications related to thymic function.
The company has not yet established the effectiveness of TLB-33 for thymic preservation, and that question will need to be addressed in future clinical trials.
The Company Plans to Start Phase 2 Development
Tolerance Bio is preparing to advance TLB-33 into Phase 2 clinical development.
The planned studies are expected to evaluate whether the antibody can preserve thymic function and improve measures of immune resilience.
The company is also considering additional immune diseases for future development.
Because TLB-33 is already a clinical-stage asset, Tolerance Bio can build on existing human safety and pharmacology information as it designs the next studies.
The results from these trials will determine whether the approach can provide meaningful benefits in the new indications being explored.
Tolerance Bio Recently Licensed an IL-7 Program
TLB-33 is not the company's only program focused on thymic biology.
Tolerance Bio recently announced a separate licensing agreement with NeoImmuneTech for efineptakin alfa, a long-acting form of interleukin-7, or IL-7.
IL-7 is another immune-signalling protein involved in the development and maintenance of immune cells.
Tolerance Bio sees the two programs as complementary approaches.
While TLB-33 is designed to block IL-33 signalling, efineptakin alfa is intended to provide long-acting IL-7 activity.
The company is developing both programs as part of its broader strategy around preserving and restoring thymic function.
The Pipeline Includes Several Types of Therapies
Tolerance Bio is building a pipeline that includes different therapeutic approaches.
These include biologic medicines, thymus-targeted messenger RNA, or mRNA, programs and cell therapies.
The company's goal is to use these different technologies to preserve, regenerate or modulate thymic function.
TLB-33 therefore adds another biologic approach to the company's clinical-stage pipeline.
The Agreement Includes Up to About $560 Million in Milestones
Under the licensing agreement, Tanabe Pharma has granted Tolerance Bio exclusive development and manufacturing rights for TLB-33 worldwide.
Tolerance Bio will also have exclusive commercialization rights outside Japan.
Tanabe Pharma will retain commercialization rights in Japan.
The agreement includes potential development and sales milestone payments of up to approximately $560 million.
Tanabe Pharma is also eligible to receive equity consideration and tiered royalties based on net sales of TLB-33.
The companies did not disclose the specific structure of the equity consideration or the individual milestone payments.
Tolerance Bio Plans to Use the Agreement to Expand Its Pipeline
The addition of TLB-33 expands Tolerance Bio's clinical-stage pipeline and gives the company another asset that already has human clinical experience.
The company said its management team has experience identifying and developing clinical-stage medicines for new indications.
This includes experience at Celimmune and Provention Bio.
Tolerance Bio plans to apply this experience to the development of TLB-33 in thymic preservation and other immune-related conditions.
What Tolerance Bio Said About TLB-33
Francisco Leon, MD, PhD, chief executive officer of Tolerance Bio, said the agreement adds another clinical-stage program to the company's work on thymic biology.
Leon described TLB-33 as a well-characterized antibody with existing human safety and pharmacology data.
He also said that IL-33 signalling has been linked to thymic involution in inflammatory settings.
According to Tolerance Bio, blocking IL-33 could potentially help preserve thymic function and support immune resilience.
These possibilities will need to be tested in clinical studies.
Financing Will Support Further Development
Tolerance Bio expects to announce the completion of a financing round to support the development of TLB-33 and efineptakin alfa.
The funding is expected to support planned clinical trials for both programs.
The company has not yet disclosed all details of the financing in the announcement.
About Tolerance Bio
Tolerance Bio is a biotechnology company focused on preserving, regenerating and modulating thymic function.
The company is developing therapies aimed at addressing immune diseases and extending healthspan.
Its pipeline includes biologics, thymus-targeted mRNA therapies and thymus cell therapies.
Tolerance Bio is backed by life-sciences investors including Columbus Venture Partners, Criteria Bio Ventures, Pacific 8 Ventures and BioAdvance Capital.
About Tanabe Pharma
Tanabe Pharma Corporation is a Japan-focused pharmaceutical company focused on developing medicines for areas with unmet medical needs.
The company was founded in 1678 and is one of Japan's oldest pharmaceutical companies.
Tanabe Pharma uses research and development, business development and strategic partnerships to advance medicines and improve patient care.
Under the new agreement, Tanabe Pharma will continue to retain commercialization rights for TLB-33 in Japan.
What Happens Next for TLB-33?
Tolerance Bio is preparing TLB-33 for Phase 2 development.
The upcoming clinical work will focus on whether blocking IL-33 can preserve thymic function and improve measures of immune resilience.
The company will also evaluate additional immune-related indications as development progresses.
The existing clinical experience with more than 150 subjects provides a starting point for the program, but new trials will be needed to establish the safety and effectiveness of TLB-33 for thymic preservation.
